Company news
CanSino Biologics, Inc. news in 2026
CanSino Biologics, Inc.'s news releases, calls and decks from 2026, newest first.
(688185)"Cansino Biologics Inc."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for Conducting Clinical Trials of the Diphtheria, Tetanus and Acellular Pertussis (Five-Component) Combined Vaccine, Adsorbed, in a Population Aged 4–5 Years
November 16, 2026
(688185)"Cansino Biologics Inc."Announcement on Convening the Q3 2026 Performance Briefing
November 16, 2026
(688185)"Cansino Biologics Inc."Announcement on Change of Sponsor Representative for Continuous Supervision and Guidance
November 2, 2026
(688185)"Cansino Biologics Inc."Report for Q3 2026
October 27, 2026
(688185)"Cansino Biologics Inc."Announcement on Satisfaction of Vesting Conditions for the First Vesting Period of the Initial Grant under the 2025 A-Share Restricted Share Incentive Plan
October 27, 2026
(688185)"Cansino Biologics Inc."Announcement on Provision for Expected Credit Losses and Asset Impairment and Write-down of Certain Deferred Tax Assets for Q3 2026
October 27, 2026
(688185)"Cansino Biologics Inc."Announcement on Cancellation of Certain Granted but Unvested Restricted Shares
October 27, 2026
Announcement on Receipt of Government Subsidies
October 12, 2026
Announcement on Granting Certain Reserved Restricted Shares to Participants under the 2025 A-Share Restricted Share Incentive Plan
September 16, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry
September 4, 2026
Semi-annual Report for 2026
August 27, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing
August 25, 2026
Announcement on Abnormal Fluctuations in Stock Trading
August 21, 2026
Announcement on Obtaining Drug Registration Certificate for Adsorbed Tetanus Vaccine
August 20, 2026
Announcement on Voluntary Disclosure of Acceptance of the Drug Registration Application for Adsorbed Tetanus, Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine (For Persons Aged 6 and Above)
August 16, 2026
CanSino Biologics: CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years
July 19, 2026
CanSino Biologics: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach
June 25, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 10, 2026
Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
May 25, 2026
Announcement on Changing Location of 2025 Annual General Meeting
May 19, 2026
Announcement on Voluntary Disclosure of Official Inclusion of the Adsorbed Acellular Pertussis (5-Component), Diphtheria and Tetanus Combined Vaccine (for People Aged 6 and Above) into the Priority Review List
May 11, 2026
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
April 30, 2026
Announcement on Amending the "Articles of Association" and Its Attachments and Formulating the "Remuneration Management System for Directors and Senior Management Members"
April 28, 2026
Announcement on Obtaining the Drug Registration Certificate for the Adsorbed Inactivated (Three-component) Diphtheria-Tetanus-Pertussis Vaccine for Infants and Young Children
April 12, 2026
Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure
March 30, 2026
Announcement on Voluntary Disclosure of Obtaining PIC/S GMP Certification
March 5, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Obtaining the Supplementary Application Approval Notice for the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Carrier)
February 24, 2026
CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines
February 9, 2026
Announcement on Earnings Preannouncement for 2025
January 27, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)
January 5, 2026